ImmunoBiology Limited (ImmBio) Company Profile
Limited [ImmBio] is a biotechnology company specialising in the treatment of infectious diseases and cancer. ImmBio's approach is to apply advances in the emerging science of Immunobiology to the development of treatments for infections diseases and cancer.
Immbio is developing a proprietary vaccine technology based on these advances. The platform technology is called HspC™ vaccination.
HspC™ vaccination is designed to elicit a broad immune response that is specific to the chosen pathogen. HspC™ vaccination thus elicits a more powerful and longer lasting immune response than any alternate treatment regimes. Immbio will initially focus on treatments for infectious diseases (e.g. tuberculosis, influenza and hepatitis).
Dr Colaco set up Immbio in May 1999 to apply the principles of Immunobiology to the treatment of infectious diseases and cancer. In September 1999, ImmBio won a SMART award to begin development of a TB vaccine and this is the initial focus of the company. In 2003 ImmBio raised further funds to complete its TB PoP studies and begin an influenza vaccine programme
Location
Babraham Bioincubator
Cambridge
Cambridgeshire
CB2 4AT
United Kingdom
Contact
Phone: 44 (0) 1223 496116
Fax: 44 (0) 1223 496116
Email: camilo.colaco@immunobiology.co.uk
News Articles
ImmBio gets Biomedical Catalyst support to develop pneumococcal vaccine PnuBioVax
Immunobiology (ImmBio), a UK-based biopharmaceutical company, has bagged £0.2m in funding from the UK government-backed Biomedical Catalyst (BBC) for the pre-clinical development of pneumococcal vacc...
CAMBRIDGE, England, March 12, 2013 /PRNewswire/ -- ImmBio (Immunobiology Ltd), a biopharmaceutical company developing innovative vaccines against serious infectious diseases, today announced that the...
Yale Wins $10 Million Grant for Novel Immunobiology Research
ImmunoBiology installs ProtoCOL 3 colony counter
Speeds up testing throughput of bacterial meningitis vaccines
Major Award for an Immunologist from the University of Freiburg
Prof. Dr. Michael Reth, professor of Molecular Immunology at the Institute of Biology III, speaker of the excellence cluster Centre for Biological Signaling Studies BIOSS and group leader at the Max...
New mechanism that plays important role in meiosis identified
The Research Group headed by molecular biologist Andrea Pichler from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg has made an important discovery in meiosis research.
Regulation of telomerase in stem cells and cancer cells
(Max-Planck-Gesellschaft) Scientists at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg have gained important insights for stem cell research which are also applicable to human t...
The American Society for Microbiology honors Akiko Iwasaki
(American Society for Microbiology) Akiko Iwasaki, Ph.D., professor, Department of Immunobiology, Yale University, is the laureate of the 2012 Eli Lilly and Company Research Award.
Drugs and Medications
None
PubMed Articles
Porcine reproductive and respiratory syndrome virus (PRRSV) is one of the most costly pathogens for the swine industry. Since its emergence some 20 years ago, much has been learned about the immunobio...
Warheads and avoiding Star Wars.
NF-κB was first discovered and characterized 25 years ago as a key regulator of inducible gene expression in the immune system. Thus, it is not surprising that the clearest biological role of NF-κB...
Clinical Trials
To learn whether or not an Interferon defect in cell signaling, recently discovered in immune cells from melanoma patients as well as breast cancer patients, is common to all cancers.
Immunobiology of Diabetes and Tuberculosis
Despite reports that diabetes mellitus increases the risk of tuberculosis by as much as 11-fold, few studies have focused on the underlying mechanism for this susceptibility. Our ultimate...
Companies
ImmunoBiology Limited (ImmBio)
Limited [ImmBio] is a biotechnology company specialising in the treatment of infectious diseases and cancer. ImmBio's approach is to apply advances in the emerging science of Immunobiology to the deve...
Maine Biotechnology Services , Inc.
Since 1990, Maine Biotechnology Services, Inc. has offered a comprehensive range of immunochemicals and contract immunobiology manufacturing services. We focus on contract hybridoma and polyclonal ant...
Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the i...
Pharmacopeia is a biopharmaceutical company developing small molecule therapeutics to meet the needs of large patient populations suffering from significant unmet medical needs. With multiple internal...
More Information about "ImmunoBiology Limited (ImmBio)" on BioPortfolio
We have published hundreds of ImmunoBiology Limited (ImmBio) news stories on BioPortfolio along with dozens of ImmunoBiology Limited (ImmBio) Clinical Trials and PubMed Articles about ImmunoBiology Limited (ImmBio) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ImmunoBiology Limited (ImmBio) Companies in our database. You can also find out about relevant ImmunoBiology Limited (ImmBio) Drugs and Medications on this site too.
